MX2023008372A - Anticuerpo multiespecifico que se une a actriia, actriib y fn14. - Google Patents
Anticuerpo multiespecifico que se une a actriia, actriib y fn14.Info
- Publication number
- MX2023008372A MX2023008372A MX2023008372A MX2023008372A MX2023008372A MX 2023008372 A MX2023008372 A MX 2023008372A MX 2023008372 A MX2023008372 A MX 2023008372A MX 2023008372 A MX2023008372 A MX 2023008372A MX 2023008372 A MX2023008372 A MX 2023008372A
- Authority
- MX
- Mexico
- Prior art keywords
- actriia
- actriib
- multispecific antibody
- polypeptide
- seq
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021003805 | 2021-01-13 | ||
| PCT/JP2022/000661 WO2022153997A1 (ja) | 2021-01-13 | 2022-01-12 | ＡｃｔＲＩＩＡ、ＡｃｔＲＩＩＢ及びＦｎ１４に結合する多重特異性抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023008372A true MX2023008372A (es) | 2023-07-26 |
Family
ID=82448440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023008372A MX2023008372A (es) | 2021-01-13 | 2022-01-12 | Anticuerpo multiespecifico que se une a actriia, actriib y fn14. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240092916A1 (https=) |
| EP (1) | EP4279594A4 (https=) |
| JP (1) | JPWO2022153997A1 (https=) |
| KR (1) | KR20230131207A (https=) |
| CN (1) | CN116802298A (https=) |
| AU (1) | AU2022207252A1 (https=) |
| CA (1) | CA3207850A1 (https=) |
| MX (1) | MX2023008372A (https=) |
| WO (1) | WO2022153997A1 (https=) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| PE20120532A1 (es) * | 2009-04-27 | 2012-05-18 | Novartis Ag | ANTICUERPOS ANTI-ActRIIB |
| HK1198832A1 (en) | 2011-08-23 | 2015-06-12 | Transbio Ltd | Fn14 binding proteins and uses thereof |
| NZ703724A (en) * | 2012-06-11 | 2017-06-30 | Amgen Inc | Dual receptor antagonistic antigen-binding proteins and uses thereof |
| HK1219280A1 (zh) * | 2013-08-14 | 2017-03-31 | Novartis Ag | 治疗偶发性包涵体肌炎之方法 |
| CA3001654A1 (en) | 2015-11-11 | 2017-05-18 | Novartis Ag | Uses of myostatin antagonists, combinations containing them and uses thereof |
| KR20200118423A (ko) * | 2018-01-08 | 2020-10-15 | 난징 레전드 바이오테크 씨오., 엘티디. | 다중특이성 항원 결합 단백질 및 이의 사용 방법 |
| MY204672A (en) * | 2018-10-31 | 2024-09-09 | Astellas Pharma Inc | Anti-human fn14 antibody |
| TW202031684A (zh) * | 2018-12-20 | 2020-09-01 | 日商協和麒麟股份有限公司 | Fn14抗體及其用途 |
-
2022
- 2022-01-12 US US18/272,020 patent/US20240092916A1/en active Pending
- 2022-01-12 CA CA3207850A patent/CA3207850A1/en active Pending
- 2022-01-12 AU AU2022207252A patent/AU2022207252A1/en not_active Abandoned
- 2022-01-12 CN CN202280009978.7A patent/CN116802298A/zh active Pending
- 2022-01-12 KR KR1020237023856A patent/KR20230131207A/ko active Pending
- 2022-01-12 MX MX2023008372A patent/MX2023008372A/es unknown
- 2022-01-12 EP EP22739403.8A patent/EP4279594A4/en active Pending
- 2022-01-12 JP JP2022575595A patent/JPWO2022153997A1/ja active Pending
- 2022-01-12 WO PCT/JP2022/000661 patent/WO2022153997A1/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230131207A (ko) | 2023-09-12 |
| CA3207850A1 (en) | 2022-07-21 |
| AU2022207252A9 (en) | 2024-10-17 |
| AU2022207252A1 (en) | 2023-08-03 |
| EP4279594A4 (en) | 2024-11-27 |
| US20240092916A1 (en) | 2024-03-21 |
| EP4279594A1 (en) | 2023-11-22 |
| CN116802298A (zh) | 2023-09-22 |
| WO2022153997A1 (ja) | 2022-07-21 |
| JPWO2022153997A1 (https=) | 2022-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR073978A1 (es) | Anticuerpos humanos de alta afinidad para el receptor il-4-humano | |
| JP2020513809A5 (https=) | ||
| MX2020011391A (es) | Anticuerpo bcma humanizado y linfocitos t car-bcma. | |
| CO6180466A2 (es) | Composiciones y metodos para diagnosticar y tratar cancer | |
| PE20220708A1 (es) | Anticuerpos anti-cd73 | |
| EA201991701A1 (ru) | Состав на основе моноклонального антитела к rsv | |
| PE20121541A1 (es) | Antigenos de virus de sincicio respiratorio recombinantes | |
| SG10201908259WA (en) | Methods of reducing serum levels of fc-containing agents using fcrn antagonsits | |
| NZ724904A (en) | Hybrid immunoglobulin containing non-peptidyl linkage | |
| TN2009000090A1 (en) | Prophylactic or therapeutic agent for canger | |
| PH12020551808A1 (en) | Antibody variant combinations and uses thereof | |
| MX2024014979A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer | |
| JOP20210093A1 (ar) | جسم مضاد fn14 غير متوافق مع الإنسان | |
| MX2024001326A (es) | Composicion farmaceutica de anticuerpo anti-pd-1 y uso de la misma. | |
| PE20211048A1 (es) | Anticuerpos injertados con peptido natriuretico tipo c | |
| MX2022010207A (es) | Anticuerpo anti-adrenomedulina (adm) o fragmento de anticuerpo anti-adm o andamiaje no ig anti-adm para usarse en terapia o prevencion de choque. | |
| ZA202110285B (en) | Antibodies and methods of use | |
| CR20220415A (es) | Anticuerpos multiespecíficos, composiciones que los comprenden, y vectores y usos de los mismos | |
| MX2023008372A (es) | Anticuerpo multiespecifico que se une a actriia, actriib y fn14. | |
| IL276911B2 (en) | Variants of the carboxylation rate of antibodies | |
| RU2584572C2 (ru) | Способ получения полипептида, конъюгированного с поли(этиленгликолевым) фрагментом, нуклеиновая кислота и слитый полипептид, предназначенные для применения в способе | |
| Ismail et al. | Biochemical characterization of riboflavin carrier protein (RCP) in prostate cancer Tanya Johnson1, 2, 7, Allal Ouhtit 3, 7, Rajiv Gaur3, 7, Augusta Fernando3, 7, Paul Schwarzenberger4, 7, Joseph Su5, 7, Mohamed | |
| AR074398A1 (es) | Anticuerpo nonoclonal o su fragmento de union a antigeno polinucleotido vector de expresion recombinante y celula huesped transformada correspondientes su uso para la preparacion de un medicamento util para el tratamiento o prevencion de anemia, composicion farmaceutica que lo comprende y proceso pa | |
| ZA202200738B (en) | Polypeptide dimer with high sialic acid content, comprising extracellular domain of alpha subunit of ige fc receptor, and pharmaceutical composition comprising same | |
| MX2018011133A (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. |